REGINA HENSLEY: Open Payments
NPI 1548325640 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,327 in 84 payments from 9 companies in 2025. Trend: 2023 $966 · 2024 $1,139 · 2025 $1,327
Food & beverage: $1,217Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $276 |
| Otsuka America Pharmaceutical, Inc. | 16 | $236 |
| Neurocrine BioSciences, Inc. | 14 | $228 |
| ABBVIE INC. | 18 | $159 |
| Alkermes, Inc. | 9 | $154 |
| Janssen Pharmaceuticals, Inc | 6 | $139 |
| E.R. Squibb & Sons, L.L.C. | 4 | $88 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: INGREZZA, VRAYLAR, INVEGA SUSTENNA, REXULTI, UZEDY, ARISTADA, COBENFY, ABILIFY MAINTENA.
Industry payments across SC — which companies pay providers there.
